-->

Ceeable VFA Overview

Ceeable Visual Field Analyzer (CVFA)

Available Anywhere

CVFA is true telemedicine – tests can be taken on a touch screen device anywhere in the world and interpreted remotely

Better Assessment

CVFA measures a 3D rather than a 2D depiction of scotomas or metamorphopsia, providing unique insight into visual field defects

Earlier Detection

CVFA can detect the early onset of glaucoma and macular degeneration before it is apparent in standard testing devices

Lower Cost

CVFA operates on a low cost tablet whereas standard visual field testing (perimetry) devices can cost more than $20k

Eyecare Anywhere

A revolutionary way to detect and treat retinopathies for billions of people worldwide


Ceeable VFA Test

Company Profile

Ceeable - A Medical Software as a Service (M-SAAS)™ Company

Ceeable Symbol

Ceeable Inc. was formed in 2014 with the intent of advancing and fully commercializing Dr. Wolfgang Fink’s revolutionary tablet-based visual field analyzer technology. The company envisions CVFA as the first of many products that will disrupt the traditional forms of patient ocular assessment, diagnosis and treatment. The company intends to accomplish this by providing innovative software-based solutions that will run on low cost commodity and ubiquitous hardware. This approach will serve as an alternative to the status-quo in the medical industry, which is typically dependent on expensive, bulky, and dedicated hardware products. The company also intends to offer its medical products through a non-traditional “software as a service” model (SAAS) where its software is cloud-based and licensed for use by clients on a subscription basis.

The company’s core competencies are deep and expansive, bringing together years of experience in the areas of medical software development, ophthalmology, vision science, biomedical engineering, information technology, regulatory navigation, research & development, and sales & marketing. The company also maintains and will utilize close relationships with several leading research & educational institutions including the University of Arizona and Caltech. Most importantly, however, the company founders have extensive and proven product commercialization experience, having successfully developed and marketed medical and other software products with revenue in excess of $40 million.

Latest News


Ophthalmology Times Logo
Ceeable Technology Profiled in Ophthalmology Times

Somerville, Mass., July 18, 2016 – Ceeable announced today that the company and the Ceeable visual field analysis technology were featured in the current online issue of Ophthalmology Times.


The Ceeable mobile digital health 3D Visual Field Analyzer (CVFA) is a comprehensive, non-invasive, web-based screening and dynamic classification system that can be easily used in clinical settings to detect early changes in visual function due to retinopathies such as glaucoma, macular degeneration, and optic neuropathy as well as progression monitoring over time.


CVFA is an accurate, low cost, and fast visual field testing system that is accessible anywhere in the world, and the technology is applicable to a wide variety of markets and conditions. The ability to provide medical professionals with an independent second opinion (diagnosis) and progression monitoring capabilities, the market applicability for CVFA is expected to expand even more.


The Ceeable technology can be used in the clinic, remote settings or by the individual patient. The Ceeable test has been used on over 3000 patients across the globe. Over 285 million people in the world are visually impaired, with conditions such as Glaucoma and diabetic retinopathy.   


AMA Logo
Ceeable Awarded AMA "Best New Idea for Creating a Healthier Nation"

Chicago, 6/13/2016 – The AMA's Healthier Nation Innovation Challenge kicked-off in April 2016 and invited all U.S. physicians, residents and medical students to be a positive force for health care and present their best ideas for shaping 21st century medicine. The three winning ideas were selected from a total of 116 solutions submitted to compete in the challenge.


Out of the 116 entries, Ceeable’s CVFA was selected as one of three winning ideas. CVFA is a visual field test that can detect, classify, and monitor degenerative eye disease using only a tablet.


As one of the three winning entries, Ceeable shares a $50,000 prize and gains access to the AMA's network of partners that specialize in strategy and design support for entrepreneurs and startups, including Business Models, Inc., Edge One Medical, Healthbox, MATTER, MU/DAI and Techstars.


ITExpo Logo
Ceeable Selected as a Finalist at the IDEA Showcase@ITEXPO

New technology will deliver rapid, accurate and low-cost visual testing for glaucoma, diabetic retinopathy and macular degeneration


Ceeable, Inc. was selected as a finalist for its mobile digital health technology at the IDEA Showcase@ITEXPO conference in Ft. Lauderdale Florida January 27-29 2016. The Ceeable Visual Field Analyzer (CVFA) is a cloud-based digital platform used to detect and classify retinal disease, including glaucoma, diabetic retinopathy and macular degeneration. The CVFA will deliver rapid, accurate and low-cost visual testing to patient populations that may not have access to traditional visual testing services.


IDEA Showcase was a forum for companies to present business models that rely on the modern telecommunications networks. There a strong emphasis on enabling technologies. The Ceeable mobile technology takes advantage of the significant telecommunications infrastructure to deliver a breakthrough product to detect retinal disease.


The CVFA can be used in both traditional clinical settings for visual exams and non- traditional settings, from shopping malls to villages. The CVFA is highly mobile and can be accessed from anywhere at any time using a tablet computer and internet connection. This flexibility provides much greater access to patients and caregivers. The Ceeable technology has been used to detect retinal disease on thousands of patients worldwide.


ITExpo Logo
Ceeable at the IDEA Showcase@ITEXPO

New technology will deliver rapid, accurate and low-cost visual testing for glaucoma, diabetic retinopathy and macular degeneration


Ceeable, Inc. will present its mobile digital health technology at the IDEA Showcase@ITEXPO conference in Ft. Lauderdale Florida January 27-29 2016. The Ceeable Visual Field Analyzer (CVFA) is a cloud-based digital platform used to detect and classify retinal disease, including glaucoma, diabetic retinopathy and macular degeneration. The CVFA will deliver rapid, accurate and low-cost visual testing to patient populations that may not have access to traditional visual testing services.


The CVFA can be used in both traditional clinical settings for visual exams and non-traditional settings, from shopping malls to villages. The CVFA is highly mobile and can be accessed from anywhere at any time using a tablet computer and internet connection. This flexibility provides much greater access to patients and caregivers. The Ceeable technology has been used to detect retinal disease on thousands of patients worldwide.


ITL Logo
5 Apps That May Transform Healthcare

"The health insurance industry should stand up and take notice."


HITLAB, a healthcare innovation technology and teaching lab based in New York, just sponsored its second annual World Cup event at Columbia University for aspiring healthcare technology entrepreneurs and start-ups. The HITLAB staff, who blew me away with their creative energy, brought together the best and the brightest in academia, the business world, the insurance industry and the healthcare technology sector for this two-day event.


Out of 192 applicants, five finalists were selected to present potentially revolutionary technology and ideas on a wide range of global public health problems that have been around since the time Moses wore short pants and that someday soon may have the kind of impact Louis Pasteur and Steve Jobs did.



HITLAB Logo
Ceeable Wins the 2015 HITLAB World Cup

New York, 12/3/2015 – Following months of anticipation among healthcare innovators and a final round of competition, the HITLAB (Healthcare Innovation Technology) World Cup Grand Prize Winner has been crowned: Ceeable, developer of the Ceeable Visual Field Analyzer (CVFA), was awarded $10,000 and the distinction “Best Health Tech Innovation of 2015.”


CVFA is a visual field test that can detect, classify, and monitor degenerative eye disease using only a tablet.


Ceeable represents the best and brightest in a crowded field; 192 teams began applications in this global contest, representing 14 countries: Cameroon, Canada, Egypt, France, Germany, India, Japan, Malaysia, Nigeria, South Africa, Sweden, Uganda, United States, and Zimbabwe. After submitting technologies and business plans, 67 teams advanced. Five finalists were ultimately chosen to present during the final session of the HITLAB Innovators Summit held in Columbia University’s Alfred Lerner Hall on December 4, 2015.


FastCompany Logo
This Simple Tablet-Based Eye Test Could Help Cure A Lot More Blindness

Mobile technology has the potential to slash the cost of medical care, spreading access to millions of people around the world. A host of procedures that once needed expensive equipment—from blood tests to ultrasounds—can now be performed with phones and mobile device attachments, and more categories are coming.


Ceeable's tablet-based eye-test is a case in point. It replaces a clinical machine that normally costs between $25,000 and $35,000 and offers a similar level of accuracy, according to peer-reviewed research. It could help detect a greater number of people with serious retinal conditions like macular degeneration and glaucoma, and save a lot of money doing it ...


MHSRS Logo
Ceeable VFA Abstract, Poster, and Presentation at MHSRS 2015

An abstract on Ceeable VFA was submitted to and accepted by the 2015 Military Health System Research Symposium (MHSRS) as a poster presentation in the topic area "Sensory Issues/Vision, Hearing & Balance". Abstracts and poster presentations at this year's symposium are in high demand with the MHSRS receiving a record 1,192 submissions. The acceptance is a testament to the Organizing Committee’s belief that Ceeable VFA and the associated research will be of high interest to the MHSRS audience and the Military Health System in general. The abstract is titled "Portable, Comprehensive, Tele-medical Assessment of Visual Performance in Warfighters, Veterans, and Civilians".


VSMA Logo
Russian eye clinic passes the 500 patient threshold

Voronezh State Medical Academy, a leading ophthalmology clinic in Russia, has been utilizing the Ceeable VFA retinal disease testing technology in both traditional clinical settings for visual exams and non-traditional settings, such as shopping malls and villages. The clinic has now successfully tested over 500 patients using the technology. The Ceeable VFA technology is highly mobile and can be accessed from anywhere at any time using a tablet computer and internet connection. This flexibility provides much greater access to patients worldwide.


About Ceeable

Ceeable, Inc. is a leader in digital mobile health for ophthalmology and Medical Software as a Service (M-SAAS). Ceeable VFA is a cloud based digital platform used to detect, classify and monitor retinal disease. There are more that 285 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease is a critical factor in blindness prevention and reduced healthcare costs.

MHSRS Logo
Ceeable begins research collaboration in Mexico

Ceeable in collaboration with Dr. Daniel Garza, Chief of Ophthalmology at UMAE hospital in Monterey, Mexico have introduced the Ceeable VFA technology into clinical practice in Mexico. The Ceeable VFA technology is currently being used at UMAE hospital to detect and monitor retinal disease in a diverse patient population. The advantage of the Ceeable VFA test is that it is a web-based platform that only requires a tablet computer and an internet connection. To date, the Ceeable VFA platform has been used on more than 100 patients in the UMAE eye clinic. The ability to rapidly detect retinal disease in large patient populations with a convenient test format will enable much more efficient and effective eye care.


Ceeable plans to expand the use of the technology throughout Mexico and Central America over the coming months.


About Ceeable

Ceeable, Inc. is a leader in digital mobile health for ophthalmology and Medical Software as a Service (M-SAAS). Ceeable VFA is a cloud based digital platform used to detect, classify and monitor retinal disease. There are more that 285 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease is a critical factor in blindness prevention and reduced healthcare costs.

NG Logo
New Governance Teams with Ceeable, Inc.

New Governance, Inc. announced that it would partner with Ceeable, Inc. the California Institute of Technology, the University of Arizona, and the Center for Military Medicine Research to commercialize Ceeable Visual Field Analyzer (CVFA), a revolutionary web-based software tool that detects and monitors retinopathies using only a touch screen device (such as an iPad®).


In multiple clinical studies since 2000, conditions such as glaucoma, age-related macular degeneration (AMD), anterior ischemic optic neuropathy, optic neuritis, ocular hypertension, macular edema, and ethambutol toxicity have been successfully detected by CVFA. Since the CVFA technology only requires a generic touch screen device, it stands to revolutionize the way retinopathies are detected and treated for billions of people worldwide.


Under the terms of the teaming agreement New Governance will work directly with Dr. Wolfgang Fink (the co-inventor of 3D-CTAG, the base technology in CVFA) and his colleagues at Caltech, the University of Arizona, and the Center for Military Medicine Research to move CVFA beyond the lab and into a fully commercialized product.


Dr Fink is the founder of the Visual and Autonomous Exploration Systems Research Laboratory at Caltech. He is also an associate Professor and the inaugural Edward & Maria Keonjian Endowed Chair in Microelectronics at the University of Arizona in Tucson, Arizona in the Departments of Electrical & Computer Engineering, Biomedical Engineering, Systems & Industrial Engineering, and Ophthalmology & Vision Science.


About Ceeable

Ceeable, Inc. is a leader in digital mobile health for ophthalmology and Medical Software as a Service (M-SAAS). Ceeable VFA is a cloud based digital platform used to detect, classify and monitor retinal disease. There are more that 285 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease is a critical factor in blindness prevention and reduced healthcare costs.

Caltech Logo
Caltech scientist, Dr. Wolfgang Fink joins Ceeable as a scientific adviser

Dr. Wolfgang Fink, professor of Physics at Caltech and the University of Arizona and the co-inventor of 3D-CTAG, the base technology used in Ceeable VFA, has joined the Ceeable scientific advisory board. Ceeable VFA is a next generation digital health platform for detecting and classifying retinal disease. Dr. Fink will work with Ceeable to help guide the technology development efforts and transition the technology to the commercial market.


About Ceeable

Ceeable, Inc. is a leader in digital mobile health for ophthalmology and Medical Software as a Service (M-SAAS). Ceeable VFA is a cloud based digital platform used to detect, classify and monitor retinal disease. There are more that 285 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease is a critical factor in blindness prevention and reduced healthcare costs.

Caltech Logo
Ceeable, Inc. launches to develop and commercialize cloud-based technology to detect and classify retinal disease based on the work of Caltech scientist

Ceeable, Inc. is formed to develop a next generation digital health technology for visual field analysis. The technology was developed by Dr. Wolfgang Fink at the California Institute of Technology. In development for the past several years the technology is a rapid and accurate way to detect and classify diseases of the retina.


The Ceeable VFA (Visual Field Analysis) technology is a patented and clinically validated platform for diagnosing retinal disease. The technology is the subject of numerous publications, awards, and conference presentations.


About Ceeable

Ceeable, Inc. is a leader in digital mobile health for ophthalmology and Medical Software as a Service (M-SAAS). Ceeable VFA is a cloud based digital platform used to detect, classify and monitor retinal disease. There are more that 285 million people worldwide that suffer from retinal disease. The Ceeable technology has the ability to reach more people worldwide than any currently available retinal diagnostic technology. Better patient management of eye disease is a critical factor in blindness prevention and reduced healthcare costs.

BCM Logo
3D-CTAG and Astronaut Ocular Health

In 2014, former Astronaut and current Associate Professor in the Departments of Internal Medicine and Pediatrics and the Center for Space Medicine at the Baylor College of Medicine David C. Hilmers and 3D-CTAG co-inventor Dr Wolfgang Fink collaborated on the use of 3D-CTAG in support of astronaut ocular health during long duration spaceflight. 3D-CTAG is the base technology for CVFA. The result was a research paper published in IEEE entitled "Portable System to Monitor Astronaut Ocular Health and the Development of the VIIP Syndrome".


The research paper proposes the use of 3D-CTAG (as a previously developed, deployed, and clinically tested comprehensive visual field test and diagnosis system) to investigate the relationship between intracranial pressure (ICP) and intraocular pressure (IOP) elevations that occur during long-term space travel and visual field loss.

AZPM Logo
Vision Testing Makes Its Way to Space

Outer space can be hard on the eyes. Exposure to radiation, intense and ultraviolet light, and low gravity cause blood to rise into the head. Because of this, 34 percent of astronauts experience some kind of vision change while in space. Testing vision while in flight, however, can be a challenge. Systems that test sight, to include peripheral vision, are bulky, making them impractical for space travel. "Most of these devices are actually at an ophthalmologist's office," said Wolfgang Fink, Ph.D., founder of the University of Arizona Visual and Autonomous Exploration Systems Research Laboratory. "So, in other words, they are not portable. One cannot self administer them."

SpaceX Logo
3D-CTAG in Support of Astronaut Health & Performance

In late 2013, former Astronaut and current SpaceX Commercial Crew Program Manager Garrett Reisman and 3D-CTAG co-inventor Wolfgang Fink collaborated on the use of 3D-CTAG in support of astronaut health and performance during long duration spaceflight. 3D-CTAG the base technology for CVFA. The result was a research paper published in IEEE entitled "Comprehensive Visual Field Test & Diagnosis System in Support of Astronaut Health and Performance".


The research paper presents 3D-CTAG as an integrated, non-invasive, comprehensive visual field test & diagnosis system for the identification, characterization, and automated classification of visual field defects caused by the spaceflight environment. This paper outlines how the system will support the onboard medical provider and astronauts or crewmembers on space missions with an innovative, non-invasive, accurate, sensitive, and fast visual field test, a relational database for examination data, and a software package for the automated analysis and diagnosis of visual field defects. It also outlines how the system will be used to detect and diagnose conditions affecting the visual field, while in space and on Earth, permitting the timely application of therapeutic countermeasures before astronaut health and performance are impaired.


Contact Us